RF Ablation System Promotional Statements Are Misleading - FDA
This article was originally published in The Gray Sheet
Executive SummaryFDA is looking into promotional statements made by RadioTherapeutics in three recent press releases regarding the firm's RF ablation system.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.